secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2026-05-22T21:24:41+00:00
Accession:  0001193125-26-237199
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Maze Therapeutics SVP Finance Amy Bachrodt to resign effective June 1, 2026
---------------------------------------------------------------------------

- Amy Bachrodt resigns as SVP, Finance, effective June 1, 2026.
- Resignation not related to any disagreement with the company.
- CFO Misbah Tahir will assume principal accounting officer role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/0001193125-26-237199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526237199/d909749d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-237199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer